Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis

Vascular Pharmacology

Volumn 63, Issue 2, 2014, Pages 79-87

  Antoniou, George A ^a   Fisher, Robert K ^a   Georgiadis, George S ^b   Antoniou, Stavros A ^c   Torella, Francesco ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Peripheral arterial disease; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DEATH; FOLLOW UP; HEART INFARCTION; HUMAN; LOWER LIMB PERIPHERAL ARTERIAL DISEASE; META ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; COHORT ANALYSIS; LEG; OBSERVATIONAL STUDY; PERIPHERAL ARTERIAL DISEASE; VASCULARIZATION;

COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEG; OBSERVATIONAL STUDY AS TOPIC; PERIPHERAL ARTERIAL DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84927673126     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.09.001     Document Type: Review

References (43)

1. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., TASC II Working Group Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. 2007, 45 Suppl S:S5-S67.
2. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., Krook S.H., Hunninghake D.B., Comerota A.J., Walsh M.E., McDermott M.M., Hiatt W.R. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286(11):1317-1324.
3. Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., Powe N.R., Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler. Thromb. Vasc. Biol. 1999, 19(3):538-545.
4. Collins R., Armitage J., Parish S., Sleight P., Peto R., Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363(9411):757-767.
5. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278(4):313-321.
6. Paraskevas K.I., Giannoukas A.D., Mikhailidis D.P. Statins and infrainguinal vascular bypass procedures. Curr. Vasc. Pharmacol. 2013, 11(1):51-57.
7. Samson R.H. The role of statin drugs in the management of the peripheral vascular patient. Vasc. Endovasc. Surg. 2008, 42(4):352-366.
8. Athyros V.G., Kakafika A.I., Tziomalos K., Karagiannis A., Mikhailidis D.P. Pleiotropic effects of statins-clinical evidence. Curr. Pharm. Des. 2009, 15(5):479-489.
9. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 1998, 339(19):1349-1357.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
12. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., Hiratzka L.F., Murphy W.R., Olin J.W., Puschett J.B., Rosenfield K.A., Sacks D., Stanley J.C., Taylor L.M., White C.J., White J., White R.A., Antman E.M., Smith S.C., Adams C.D., Anderson J.L., Faxon D.P., Fuster V., Gibbons R.J., Halperin J.L., Hiratzka L.F., Hunt S.A., Jacobs A.K., Nishimura R., Ornato J.P., Page R.L., Riegel B., American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, ACC/AHA Task Force on Practice Guidelines, American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for Vascular Nursing, TransAtlantic Inter-Society Consensus, Vascular Disease Foundation ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J. Am. Coll. Cardiol. 2006, 47(6):1239-1312.
13. Higgins J.P., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A., Cochrane Bias Methods Group, Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
14. Higgins J.P., Altman D.G. Cochrane handbook for systematic reviews of interventions. Version 5.0.1. Chapter 8: assessing risk of bias in included studies 2008, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, John Wiley & Sons, Ltd., London, (Available at: http://hiv.cochrane.org/sites/hiv.cochrane.org/files/uploads/Ch08_Bias.pdf; last accessed April 2014).
15. Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available at:, (last accessed April 2014). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
16. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
17. Westin G.G., Armstrong E.J., Bang H., Yeo K.K., Anderson D., Dawson D.L., Pevec W.C., Amsterdam E.A., Laird J.R. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J. Am. Coll. Cardiol. 2014, 63(7):682-690.
18. Faglia E., Clerici G., Scatena A., Caminiti M., Curci V., Morabito A., Prisco V., Greco R., Edmonds M. Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: an observational study. Diabetes Res. Clin. Pract. 2014, 103(2):292-297.
19. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL; on Behalf of the REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. doi:10.1093/eurheartj/ehu080.
20. Tomoi Y., Soga Y., Iida O., Hirano K., Suzuki K., Kawasaki D., Yamauchi Y., Miyashita Y., Tazaki J., Nobuyoshi M. Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia. Cardiovasc. Interv. Ther. 2013, 28(4):374-382.
21. Aiello F.A., Khan A.A., Meltzer A.J., Gallagher K.A., McKinsey J.F., Schneider D.B. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J. Vasc. Surg. 2012, 55(2):371-379.
22. Vidula H., Tian L., Liu K., Criqui M.H., Ferrucci L., Guralnik J.M., Green D., Ridker P., McDermott M.M. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. Am. J. Cardiol. 2010, 105(9):1348-1352.
23. Schanzer A., Hevelone N., Owens C.D., Beckman J.A., Belkin M., Conte M.S. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J. Vasc. Surg. 2008, 47(4):774-781.
24. Isma N., Barani J., Mattiasson I., Lindblad B., Gottsäter A. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology 2008, 59(5):542-548.
25. Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. 2007, 45(4):645-654.
26. Feringa H.H., Karagiannis S.E., Vidakovic R., Elhendy A., Schouten O., Boersma E., Bax J.J., Poldermans D. Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease. Ann. Vasc. Surg. 2007, 21(6):780-789.
27. Schillinger M., Exner M., Mlekusch W., Amighi J., Sabeti S., Muellner M., Rumpold H., Wagner O., Minar E. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur. Heart J. 2004, 25(9):742-748.
28. Abbruzzese T.A., Havens J., Belkin M., Donaldson M.C., Whittemore A.D., Liao J.K., Conte M.S. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J. Vasc. Surg. 2004, 39(6):1178-1185.
29. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108(12):1481-1486.
30. Aronow W.S., Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol>or =125mg/dl treated with statins versus no lipid-lowering drug. Am. J. Cardiol. 2002, 90(7):789-791.
31. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995, 333(20):1301-1307.
32. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279(20):1615-1622.
33. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326(7404):1423.
34. Plehn J.F., Davis B.R., Sacks F.M., Rouleau J.L., Pfeffer M.A., Bernstein V., Cuddy T.E., Moyé L.A., Piller L.B., Rutherford J., Simpson L.M., Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999, 99(2):216-223.
35. Steg P.G1., Bhatt D.L., Wilson P.W., D'Agostino R., Ohman E.M., Röther J., Liau C.S., Hirsch A.T., Mas J.L., Ikeda Y., Pencina M.J., Goto S., Registry Investigators R.E.A.C.H. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297(11):1197-1206.
36. Cacoub P.P1., Abola M.T., Baumgartner I., Bhatt D.L., Creager M.A., Liau C.S., Goto S., Röther J., Steg P.G., Hirsch A.T., REACH Registry Investigators Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis 2009, 204(2):e86-e92.
37. Adam D.J., Beard J.D., Cleveland T., Bell J., Bradbury A.W., Forbes J.F., Fowkes F.G., Gillepsie I., Ruckley C.V., Raab G., Storkey H. BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366(9501):1925-1934.
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
39. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014, 63(25 Pt B):2889-2934.
40. Alnaeb M.E., Alobaid N., Seifalian A.M., Mikhailidis D.P., Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann. Vasc. Surg. 2006, 20(5):696-705.
41. Pollak A.W., Kramer C.M. LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?. Clin. Lipidol. 2012, 7(2):141-149.
42. Blum A.S. Management of dyslipidemia with statins in the patient with peripheral arterial disease. Tech. Vasc. Interv. Radiol. 2006, 9(2):50-55.
43. Coppola G., Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch. Med. Res. 2007, 38(5):479-488.